The importance of MRD-guided therapy in ALL

Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides insight on the use of measurable residual disease (MRD) as a prognostic feature for patients with acute lymphoblastic leukemia (ALL). Dr Short highlights cases where MRD status is used to make treatment decisions, such as whether patients should undergo allogeneic stem cell transplantation (alloSCT). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

• #education
• #speaker_nicholas_short
• #institution_the_university_of_texas_md_anderson_cancer_center
• #event_soho_2023
• #format_interview
• #subject_acute_lymphoblastic_leukemia
• #subject_leukemia
• #field_mrd
• #field_transplantation
• #field_clinical_practice
• #field_treatment
• #field_immuno_oncology
• #field_car_t_cellular_therapy
• #medicines_car_t
• #medicines_antibodies
• #medicines_blinatumomab
• #ph_all
• #b_cell_all
• #ngs
• #pcr
• #bcr_abl
• #allosct